Announcement of Resolutions of the First Extraordinary General Meeting of Shareholders in 2020
Release time:
2021-05-20
证券代码:600668 证券简称:尖峰集团 公告编号:2020-031
浙江尖峰集团股份有限公司
2020年第一次临时股东大会决议公告
|
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 |
重要内容提示:
- 本次会议是否有否决议案:无
- 会议召开和出席情况
- 股东大会召开的时间:2020年11月17日
- 股东大会召开的地点:浙江省金华市婺城区婺江东路88号尖峰大厦三楼会议室
- 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况:
|
1、出席会议的股东和代理人人数 |
127 |
|
2、出席会议的股东所持有表决权的股份总数(股) |
64,843,258 |
|
3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例(%) |
18.8451 |
- 表决方式是否符合《公司法》及《公司章程》的规定,大会主持情况等。
本次会议采取现场投票与网络投票相结合的方式召开及表决。会议由公司董事会 召集,董事长蒋晓萌先生主持。会议的召集、召开符合有关法律、法规、规章和 《公司章程》的规定。
- 公司董事、监事和董事会秘书的出席情况
- 公司在任董事8人,出席8人;
- 公司在任监事5人,出席5人;
- 公司董事会秘书出席了会议;部分高级管理人员列席了本次会议。
- 议案审议情况
- 非累积投票议案
1、议案名称:关于董事会换届选举的议案
审议结果:通过
1.01议案名称:选举蒋晓萌为第十一届董事会董事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,625,036 |
95.0369 |
3,218,222 |
4.9631 |
0 |
0.0000 |
1.02议案名称:选举虞建红为第十一届董事会董事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,265,336 |
94.4821 |
3,519,522 |
5.4277 |
58,400 |
0.0902 |
1.03议案名称:选举刘波为第十一届董事会董事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,294,836 |
94.5276 |
3,490,022 |
5.3822 |
58,400 |
0.0902 |
1.04议案名称:选举张国平为第十一届董事会董事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,331,936 |
94.5849 |
3,452,922 |
5.3250 |
58,400 |
0.0901 |
1.05议案名称:选举黄速建为第十一届董事会董事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,347,636 |
94.6091 |
3,437,222 |
5.3008 |
58,400 |
0.0901 |
1.06议案名称:选举黄金龙为第十一届董事会董事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,367,936 |
94.6404 |
3,416,922 |
5.2695 |
58,400 |
0.0901 |
1.07议案名称:选举傅颀为第十一届董事会独立董事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,371,736 |
94.6462 |
3,413,122 |
5.2636 |
58,400 |
0.0902 |
1.08议案名称:选举沈卫国为第十一届董事会独立董事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,375,736 |
94.6524 |
3,409,122 |
5.2574 |
58,400 |
0.0902 |
1.09议案名称:选举杨大龙为第十一届董事会独立董事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,351,736 |
94.6154 |
3,433,122 |
5.2944 |
58,400 |
0.0902 |
2、议案名称:关于监事会换届选举的议案
审议结果:通过
2.01议案名称:选举陈天赐为第十届监事会监事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,366,736 |
94.6385 |
3,416,122 |
5.2682 |
60,400 |
0.0933 |
2.02议案名称:选举吕瑞美为第十届监事会监事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,387,536 |
94.6706 |
3,397,322 |
5.2392 |
58,400 |
0.0902 |
2.03议案名称:选举石富为第十届监事会监事
审议结果:通过
表决情况:
|
股东类型 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
|
|
A股 |
61,379,236 |
94.6578 |
3,405,622 |
5.2520 |
58,400 |
0.0902 |
- 涉及重大事项,5%以下股东的表决情况
|
议案 序号 |
议案名称 |
同意 |
反对 |
弃权 |
|||
|
票数 |
比例(%) |
票数 |
比例(%) |
票数 |
比例(%) |
||
|
1.01 |
选举蒋晓萌为第十一届董事会董事 |
6,020,521 |
65.1660 |
3,218,222 |
34.8340 |
0 |
0.0000 |
|
1.02 |
选举虞建红为第十一届董事会董事 |
5,660,821 |
61.2726 |
3,519,522 |
38.0952 |
58,400 |
0.6322 |
|
1.03 |
选举刘波为第十一届董事会董事 |
5,690,321 |
61.5919 |
3,490,022 |
37.7759 |
58,400 |
0.6322 |
|
1.04 |
选举张国平为第十一届董事会董事 |
5,727,421 |
61.9935 |
3,452,922 |
37.3743 |
58,400 |
0.6322 |
|
1.05 |
选举黄速建为第十一届董事会董事 |
5,743,121 |
62.1634 |
3,437,222 |
37.2044 |
58,400 |
0.6322 |
|
1.06 |
选举黄金龙为第十一届董事会董事 |
5,763,421 |
62.3831 |
3,416,922 |
36.9847 |
58,400 |
0.6322 |
|
1.07 |
选举傅颀为第十一届董事会独立董事 |
5,767,221 |
62.4243 |
3,413,122 |
36.9435 |
58,400 |
0.6322 |
|
1.08 |
选举沈卫国为第十一届董事会独立董事 |
5,771,221 |
62.4675 |
3,409,122 |
36.9002 |
58,400 |
0.6323 |
|
1.09 |
选举杨大龙为第十一届董事会独立董事 |
5,747,221 |
62.2078 |
3,433,122 |
37.1600 |
58,400 |
0.6322 |
- 关于议案表决的有关情况说明
无
- 律师见证情况
- 本次股东大会见证的律师事务所:浙江一剑律师事务所
律师:陈雄武、洪高翔
- 律师见证结论意见:
尖峰集团2020年第一次临时股东大会的召集和召开程序、参加会议人员资格、本次股 东大会的议案和表决程序等事宜,均符合法律、法规和《公司章程》的有关规定, 本次股东大会的表决结果合法有效。
- 备查文件目录
- 经与会董事和记录人签字确认并加盖董事会印章的股东大会决议;
- 经见证的律师事务所主任签字并加盖公章的法律意见书;
- 本所要求的其他文件。
浙江尖峰集团股份有限公司
2020年11月18日
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31